Oncotype DX Genomic Prostate Score predicts for long-term clinical outcomes

JCO Precision Oncology recently published the paper, “GPS Assay Association With Long-Term Cancer Outcomes: Twenty-Year Risk of Distant Metastasis and Prostate Cancer–Specific Mortality.” In this video, senior author Eric A. Klein, MD, discusses the background behind the study and what impresses him about the Oncotype DX Genomic Prostate Score. Klein is the Chairman of the Glickman Urological & Kidney Institute and a staff member in the Taussig Cancer Institute at Cleveland Clinic.